Oscar Segurado
Oscar Segurado, MD, Ph.D., is an executive veteran with extensive global leadership experience in translational science, clinical development, and global regulatory and medical affairs. He is the chief medical officer for ASC Therapeutics, a fast-growing biotechnology company focused on developing curative gene- and cell-based therapies for rare blood disorders. Segurado is the author and co-author of over 100 peer-reviewed publications, including Nature and Lancet, books, and medical articles, as well as a member of several scientific and medical societies, including his role as a Forbes Council Board Member. He also holds a tenured Professorship of Immunology at the University of Leon, Spain. He received his Ph.D. from the University of Wuerzburg, Germany, and MD from the University of Salamanca, Spain.
ARTICLES BY OSCAR SEGURADO
-
![Solidarity laboratory-GettyImages-1302453852]( "When Workers Are Down, Clinical Leaders Must Rise Up")
8/30/2023There's no surprise in saying that sponsors, CROs, and sites alike are experiencing a worker shortage. To help mitigate some of those troubles, ASC Therapeutics CMO Oscar Segurado, MD, PhD outlines some ways in which clinical research leaders can attract and retain staff and mitigate burnout.
-
Assessing Specialized Services Provided By CROs8/23/2023
Once upon a time, a CRO's main role was to provide clinical trial site and data management. Now, CROs offer a wide range of services, from those that specialize in certain therapeutic areas to those that offer the latest technology. Here's a breakdown of the types of CROs and the services they offer.
-
4 Essential Drivers In Clinical Development For Emerging Biotechs12/21/2022
Enrollment, enrollment, enrollment has been the sponsor’s classic mantra for achieving success in a clinical trial. Rather, we should replace this notion with four equally essential building blocks: 1) the selection of the right CRO, 2) the identification of study sites, 3) the engagement of sites, and 4) the enrollment of patients.